Sequence of treatment is important in the modification of camptothecin induced cell killing by hyperthermia

References

• Bichay T. J., Feeley M. M., Raaphorst G. P. A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Research 1992; 2: 63–69
   PubMed Web of Science ®Google Scholar
• Chow K. C., Ross W. E. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Molecular and Cellular Biology 1987; 7: 3119–3123
   PubMed Web of Science ®Google Scholar
• Bino G., Skierski J. S., Darzynkiewicz Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KGl) leukemic cells. Cancer Research 1990; 50: 5746–5750
   PubMedGoogle Scholar
• Del Bino G., Lassota P., Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Experimental Cell Research 1991; 193: 27–35
   PubMed Web of Science ®Google Scholar
• Dewhirst M. Future directions in hyperthermic biology. International Journal of Hyperthermia 1994; 10: 339–345
   PubMed Web of Science ®Google Scholar
• Dynlacht J. R., Wong R. S. L., Albright N., Dewey W. C. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Research 1994; 54: 4129–4137
   PubMed Web of Science ®Google Scholar
• Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–1048
   PubMed Web of Science ®Google Scholar
• Goswami P. C., Hill M., Higashikubo R., Wright W. D., Roti Roti J. L. The suppression of the synthesis of a nuclear protein in cells blocked in G2 phase: identification of NP-170 as topoisomerase II. Research Research 1992; 132: 162–167
   Google Scholar
• Hahn G. M. Hyperthermia and Cancer. Plenum Press, New York 1982; 74–85
   Google Scholar
• Hall E. J. Radiobiology for the Radiologist. J. P. Lippincott, Philadelphia 1994, edn 4
   Google Scholar
• Heck M. M. S., Hittelman W. N., Earnshaw W. C. Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. PNAS USA 1988; 85: 1086–1090
   PubMed Web of Science ®Google Scholar
• Herman T. S., Teicher B. A. Summary of studies adding systemic chemotherapy to local hyperthermia and radiation. International Journal of Hyperthermia 1994; 10: 443–449
   PubMed Web of Science ®Google Scholar
• Hochhauser D., Harris A. L. The laboratory-clinic interface. The role of topoisomerase II α and β in drug resistance. Cancer Treatment Reviews 1993; 19: 181–194
   PubMedGoogle Scholar
• Holden J. A., Rolfson D. H., Wiltwer C. T. Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990; 29: 2127–2134
   PubMed Web of Science ®Google Scholar
• Hsiang Y. H., Lihou M. G., Liu L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA Cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Research 1989; 49: 5077–5082
   PubMed Web of Science ®Google Scholar
• Husain I., Mohler J. L., Seigler H. F., Besterman J. M. Elevation of topoisomerase I-messenger RNA, protein and catalytic activity in human tumors: Demonstration of tumor type specificity and implications for cancer chemotherapy. Cancer Research 1994; 54: 539–546
   PubMed Web of Science ®Google Scholar
• Kampinga H. H. Hyperthermia, thermotolerance and topoisomerase II inhibitors. British Journal of Cancer 1995; 72: 333–338
   PubMed Web of Science ®Google Scholar
• Kondo T., Ueda K., Kano E. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells. Anticancer Research 1995; 15: 83–86
   PubMed Web of Science ®Google Scholar
• Lepock J. Involvement of membranes in cellular responses to hyperthermia. Radiation Research 1982; 92: 433–438
   PubMed Web of Science ®Google Scholar
• Liu L. F. Topoisomerases poisons as antitumor drugs. Annals of Review in Biochemistry 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Mackey M. A., Dewey W. C. Cell cycle progression during chronic hyperthermia in S phase CHO cells. International Journal of Hyperthermia 1989; 5: 405–413
   PubMed Web of Science ®Google Scholar
• Matsuo K., Kohno K., Satao S., Uchiumi K. T., Tanimura H., Yamada Y., Kuwano M. Enhanced expression of DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Research 1993; 53: 1085–1090
   PubMed Web of Science ®Google Scholar
• Ng C. E., Bussey A. M., MacDonald H. A., Heller D. P., Wilkins D. E., Raaphorst G. P. Cross sensitivity to x-radiation and type I and II DNA topoisomerase inhibitors in a range of human and rodent cell lines. International Journal of Oncology 1995; 1: 1179–1184
   Google Scholar
• Ng C. E., Bussey A. M., Raaphorst G. P. Reduction of etoposide induced cell killing by hyperthermia can occur without changes in etoposide transport or DNA topoisomerase II activity. International Journal of Hyperthermia 1996, (in press)
   Google Scholar
• O'Connor P. M., Nieves-Neira W., Kerrigan D., Pommier Y., Bertrand R., Golman J., Kahn K. W. S phase population analysis does not correlate with cytotoxicity of camptothecin and 10, 11-methylene-dioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Communications 1991; 3: 233–240
   PubMedGoogle Scholar
• Pommier Y., Leteurtre F., Fesen M. R., Fujimori A. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigations 1994; 12: 530–542
   PubMed Web of Science ®Google Scholar
• Potmesil M., Hsiang Y., Liu L. F., Bank B., Grossberg H., Kirschenbaum S., Forlenzar T. J., Penziner A., Kanganis D., Knowles D., Troganos F., Silber R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Research 1988; 48: 3537–3543
   PubMed Web of Science ®Google Scholar
• Potmesil M., Pinedo H. E. Camptothecins: New anticancer agents. CRC Press, Boca Raton 1995, Chapter 1
   Google Scholar
• Prosperi E., Sala E., Negri C., Oliani C., Supino R., Giulia B. C., Ricotti A., Bottiroli G. Topoisomerase IIα and β in human tumor cells grown in vitro and in vivo. Anticancer Research 1992; 12: 2093–2100
   PubMedGoogle Scholar
• Read R. A., Fox M. H., Bedford J. S. The cell cycle dependence of thermotolerance II. CHO cells heated at 45.0°C. Radiation Research 1984; 98: 491–505
   PubMed Web of Science ®Google Scholar
• Ryan A. J., Squires S., Strutt H. L., Johnson R. T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Research 1991; 9: 3295–3300
   Google Scholar
• Sapareto S. A., Hopwood L. E., Dewey W. C., Faju M. R., Gray J. W. Effect of hyperthermia on survival and progression of CHO cells. Cancer Research 1978; 38: 393–400
   PubMed Web of Science ®Google Scholar
• Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufman S. H. The current status of camptothecin analogues as antitumor agents. Journal of the National Cancer Institute 1993; 85: 271–291
   PubMed Web of Science ®Google Scholar
• Sullivan D. M., Glisson B. S., Hodges P. K., Smallwood-Kentzo S., Ross W. E. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986; 25: 2248–2256
   PubMed Web of Science ®Google Scholar
• Takano H., Kohno K., Ono M., Uchida Y., Kuwano M. Increased phophorylation of DNA topoisomerase II in etoposide resistance mutants of human cancer KB cells. Cancer Research 1991; 51: 3951–3957
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Holden S. A., Khandakar V., Herman T. S. Addition of a topoisomerase I inhibitor to trimodality [cisdiamminedichloroplatinum (II)/heat/radiation] in a murine tumour. Journal of Cancer Research and Clinical Oncology 1993; 119: 645–651
   PubMed Web of Science ®Google Scholar
• Toffoli G., Bevilacqua C., Franchechin A., Boiocchi M. Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukemia cell lines. International Journal of Hyperthermia 1989; 5: 163–172
   PubMed Web of Science ®Google Scholar
• Tricoli J. V., Sahi B. M., McCormick P. J., Jarlinski S. J. DNA topoisomerase I and II activities during cell proliferation and the cell cycle in culture mouse embryo fibroblast (C3H 10T1/2) cells. Experimental Cell Research 1985; 158: 1–14
   PubMedGoogle Scholar
• Tsao Y., Russo A., Nyamuswa G., Silber R., Liu L. F. Interaction between replication forks and topoisomerase I — DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Research 1993; 53: 5908–5914
   PubMed Web of Science ®Google Scholar
• Warters R. L., Barrows L. R. The heat sensitivity of HeLa S3 cell DNA topoisomerase II. Journal of Cellular Physiology 1994; 159: 468–474
   PubMed Web of Science ®Google Scholar
• Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation and cell-cycle dependence differences in expressions of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation 1991; 2: 209–214
   PubMedGoogle Scholar